X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Endoxifen (z-endoxifen) is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Lead Product(s): Endoxifen
Therapeutic Area: Oncology Product Name: Endoxifen
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Atossa Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Details:
(Z)-endoxifen is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Lead Product(s): Endoxifen
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Atossa Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Details:
ALX148 (evorpacept), is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is being investigated in combination with enhertu for breast cancer.
Lead Product(s): Evorpacept,Fam-trastuzumab Deruxtecan-nxki
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: ALX Oncology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
Oral paclitaxel, relative to intravenous paclitaxel, was associated with less neuropathy and was not associated with an increase in febrile neutropenia.
Lead Product(s): Paclitaxel,Encequidar,Dostarlimab
Therapeutic Area: Oncology Product Name: Taxol
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Athenex
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
OMS721 (narsoplimab) was not observed to shorten the time to recovery in critically ill patients with COVID-19 in this study. The study did not identify any new safety signals for narsoplimab in the setting of critically ill COVID-19 patients.
Lead Product(s): Narsoplimab
Therapeutic Area: Infections and Infectious Diseases Product Name: OMS721
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Omeros
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Details:
OMS721 (narsoplimab) was selected for inclusion in the I-SPY COVID Trial because of its demonstrated ability to inhibit complement activation, inflammation, and coagulation, the three components that characterize COVID-19.
Lead Product(s): Narsoplimab
Therapeutic Area: Infections and Infectious Diseases Product Name: OMS721
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Omeros
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Details:
The lead product candidate, evorpacept (ALX148), is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain.
Lead Product(s): Evorpacept,Deruxtecan
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: ALX Oncology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2022
Details:
To minimize potential toxicity a relatively low oral dose of 5 mg/kg/day for a duration of 5 days was selected to be administered to patients randomized into the CSA (cyclosporine) arm.
Lead Product(s): Cyclosporine,Remdesivir
Therapeutic Area: Infections and Infectious Diseases Product Name: CsA
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
ARX788 is an anti-HER2 antibody drug conjugate (ADC), is a homogeneous and highly stable ADC that maximizes potential anti-tumor activity by optimizing the number and position of its payloads and the chemical bonds that conjugate the payloads to the antibody.
Lead Product(s): ARX788
Therapeutic Area: Oncology Product Name: ARX788
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Ambrx Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Details:
Aviptadil is a synthetic form of Human Vasoactive Intestinal Polypeptide and was selected because of the potential to reduce inflammation and stabilize the air sacs of hospitalized because of injury from acute respiratory distress syndrome, which is the major cause of death.
Lead Product(s): Aviptadil Acetate,Remdesivir
Therapeutic Area: Infections and Infectious Diseases Product Name: Zyesami
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: NRx Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
